PRESS RELEASE published on 04/22/2025 at 22:00, 1 year 1 month ago Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Abivax appoints Dominik Höchli, MD to Board of Directors, bringing extensive immunology expertise ahead of key Phase 3 data readout in ulcerative colitis in Q3 2025 Board Of Directors Abivax Ulcerative Colitis Dominik Höchli Phase 3 Data Readout
BRIEF published on 04/18/2025 at 18:05, 1 year 1 month ago ABIVAX: Share Capital and Voting Rights as of March 31, 2025 Euronext Paris Share Capital Voting Rights Actions Abivax
BRIEF published on 04/18/2025 at 18:05, 1 year 1 month ago ABIVAX: Details of Share Capital and Voting Rights as of March 31, 2025 Euronext Paris Share Capital Voting Rights Biotechnology Abivax
BRIEF published on 03/27/2025 at 18:05, 1 year 2 months ago ABIVAX: Update of share capital and voting rights Share Capital Voting Rights Biotechnology AMF Abivax
BRIEF published on 03/26/2025 at 22:10, 1 year 2 months ago Abivax publishes its 2024 financial reports Biotechnology AMF Abivax Financial Reports DRY
PRESS RELEASE published on 03/26/2025 at 22:05, 1 year 2 months ago Abivax publishes financial reports with the French and U.S. securities regulatory agencies Abivax publishes financial reports with French and U.S. securities regulatory agencies. The company filed its Universal Registration Document and Annual Report for 2024 Abivax Financial Reports Regulatory Agencies U.S. Securities French
BRIEF published on 03/24/2025 at 08:35, 1 year 2 months ago Abivax Publishes its Financial Results for 2024 Financial Results Biotechnology Research And Development Treasury Clinical Trials
PRESS RELEASE published on 03/24/2025 at 08:30, 1 year 2 months ago Abivax Announces Full Year 2024 Financial Results Abivax announces full year 2024 financial results, cash balance of EUR 144.2M, ABTECT trial progress. CEO optimistic about 2025 milestones and financial outlook Financial Results Cash Position Abivax ABTECT Trial Clinical Progress
BRIEF published on 03/14/2025 at 15:21, 1 year 2 months ago JP Morgan Chase Reduces Stake in ABIVAX Actions Abivax Regulation Threshold Crossing JP Morgan Chase
BRIEF published on 03/13/2025 at 12:43, 1 year 2 months ago JP Morgan Crosses Threshold in ABIVAX Voting Rights Actions Abivax Threshold Crossing JP Morgan
Published on 06/10/2026 at 14:30, 3 hours 27 minutes ago Agassi Sports Entertainment Signs Tennis Coaching Icon Darren Cahill to Expand Global Coaching, Content and Technology Initiatives
Published on 06/10/2026 at 14:30, 3 hours 27 minutes ago Ondas to Launch LADOS, a Layered Autonomous Defense Operational C2 Layer, at Eurosatory 2026
Published on 06/10/2026 at 13:00, 4 hours 57 minutes ago Galway Metals Reports 5.0 g/t Gold over 10.85 Metres at North Deposit and Continues to Intersect Gold in Northern Extension
Published on 06/10/2026 at 13:00, 4 hours 57 minutes ago Jaguar Mining Inc. Accelerates 5-Year Exploration Plan with Tier 1 Drilling Partnerships
Published on 06/10/2026 at 17:20, 36 minutes ago TOUGHBOOK GUARD SETS NEW STANDARDS FOR HARDWARE-BASED ENDPOINT SECURITY
Published on 06/10/2026 at 17:10, 46 minutes ago FP Markets: AI remains centre stage as London Tech Week opens its doors
Published on 06/10/2026 at 17:05, 51 minutes ago TeamViewer Named a Leader in the Gartner® Magic Quadrant™ for Digital Employee Experience (DEX) Management Tools 2026 for the Third Consecutive Year
Published on 06/10/2026 at 16:40, 1 hour 16 minutes ago Healthcare Holding Schweiz acquires Compet Medical
Published on 06/10/2026 at 07:00, 10 hours 57 minutes ago Acceleration of Museum Studio's international expansion
Published on 06/09/2026 at 19:30, 22 hours 27 minutes ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 06/09/2026 at 18:14, 23 hours 43 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/05/2026
Published on 06/09/2026 at 15:17, 1 day 2 hours ago Statement of transactions in own shares from June 1, 2026 to June 5, 2026
